Clinical study on the efficacy and safety of autologous micrograft (Rigenera) and dental pulp-derived stem cell conditioned medium (SHED-CM) on hair loss - Clinical study of autologous micrograft and SHED-CM

Tokyo Midtown Center for Advanced Medical Science and Technology0 个研究点目标入组 33 人开始时间: 2021年10月28日最近更新: 2023年11月20日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 33

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

SHED-CM was effective for 75% of subjects regardless of disease severity, concomitant DHT-inhibitor use, and age. We also found that clinical hair status evaluated by absolute values of three quantitative trichoscopic factors (maximum hair diameter, vellus hair rate, and multi-hair follicular unit rate) showed a good correlation with H-N C stages, and what is more, a scoring system of these three factors can be a possible predictor of SHED-CM efficacy.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•1) those who were diagnosed as having alopecia areata subtype 2) those with nickel allergy (in case of RIGENERA treatment) 3) those with connective tissue disease or systemic diseases such as chronic thyroiditis which are associated with alopecia 4) those with hair loss due to infection or malignant tumor 5) those with immunosuppressive treatment 6) those with diagnosis of malignant tumor (including pre-cancerous lesions), except for those who have no signs of recurrence for 5 years after being diagnosed as complete remission following the standard cancer treatment 7) those with skin diseases that could affect the scalp such as seborrheic dermatitis, scalp psoriasis, atopic dermatitis, etc.) and keloids 8) those with autoimmune diseases, hematological diseases, platelet dysfunction 9) those with heart failure, renal stone, severe renal failure, liver dysfunction, hypothyroidism 10) those with fever associated with acute infection 11) those suspicious of having immunodeficiency or opportunistic infection 12) those taking anticoagulant therapy 13) those who cannot commute to the study site 14) those who are diagnosed as being difficult to undergo treatment due to the presence of mental illness or mental symptoms 15) those who are not appropriate to participate in the study according to the doctor's decision

研究者

发起方

Tokyo Midtown Center for Advanced Medical Science and Technology

相似试验

已完成

不适用

Retrospective Study on the Safety and Therapeutic/Improvement Effects of Intravenous Administration of SHED-CM for ALS (SHED-CAH2023)Amyotrophic Lateral Sclerosis

NCT06608719Hitonowa Medical24

招募中

2 期

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma PatientsEosinophilic Asthma Patients

NCT06441812Guangdong Hengrui Pharmaceutical Co., Ltd200

已完成

2 期

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil PhenotypeAsthma With Eosinophilic Phenotype

NCT05522439Jiangsu HengRui Medicine Co., Ltd.85

招募中

3 期

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisComplicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

NCT06569056Jiangsu HengRui Medicine Co., Ltd.578

招募中

1 期

Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineBurkitt LymphomaLymphoblastic Lymphoma, AdultAcute Lymphoblastic Leukemia, Adult

NCT06060782Fifth Affiliated Hospital, Sun Yat-Sen University28